Survodutide

Beginner Protocol

Intermediate Protocol

Advanced Protocol

Reconstitute with bacteriostatic water. A 5mg vial + 1mL BAC water = 5mg/mL. Use ~12 units = 600mcg starting dose on a 100-unit insulin syringe.

Stacking Notes

Additional Dosage Notes

Human evidence for survodutide comes from two Phase 2 randomized, double-blind, placebo-controlled trials sponsored by Boehringer Ingelheim; the compound is investigational and not FDA-approved. Obesity: a 46-week dose-finding trial in 387 adults with BMI >=27 and without diabetes (le Roux et al., Lancet Diabetes Endocrinol 2024; NCT04667377) found once-weekly subcutaneous survodutide reduced body weight dose-dependently, from about -6% at 0.6 mg up to about -15% at 4.8 mg versus about -3% for placebo at week 46 (planned-treatment analysis) [PMID:38330987]. MASH: a 48-week trial in 293 adults with biopsy-confirmed MASH and F1-F3 fibrosis (Sanyal et al., N Engl J Med 2024; NCT04771273) met its primary endpoint, with histologic improvement in MASH and no worsening of fibrosis in 47% (2.4 mg), 62% (4.8 mg), and 43% (6.0 mg) versus 14% for placebo; fibrosis improved by at least one stage in 34-36% of survodutide groups versus 22% for placebo [PMID:38847460]. Gastrointestinal effects (nausea, diarrhea, vomiting) were the most common adverse events in both trials. These are Phase 2 investigational results that supported progression to Phase 3 (e.g., the SYNCHRONIZE program) and are not evidence of regulatory approval or of long-term safety.

Trial-reported AEs include: nausea (most common, dose-dependent), vomiting, diarrhea, constipation, decreased appetite, injection-site reactions. Less commonly: tachycardia, blood-pressure changes (glucagon arm). Black box class concerns for GLP-1 family: thyroid C-cell tumor signal in rodents, pancreatitis risk.